Please login to the form below

Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?

In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy Watch patient record data, uptake of biosimilars remains relatively muted, with marked inconsistencies across the major European markets. With Enbrel biosimilar Benepali about to launch across EU, we ask what’s next for RA?

3rd June 2016



Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Chester House
Fulham Green
81-83 Fulham High Street
United Kingdom

Latest content on this profile

Navigating challenges of MedTech research with rare-disease patients
Authored by: Tom Donnelly, MedTech Director and Amanda Pirraglia, Associate Director. Published in Quirk's Magazine.
Research Partnership
Product launch: What market research when?
Get the insights you need, when you need them, for your product launch planning
Research Partnership
Therapy Watch launches new tracker covering Alzheimer’s Disease
The new Therapy Watch Alzheimer’s Disease tracker has recently launched in Germany, Japan and the US, with planned expansion into the remaining key European markets throughout 2024.
Research Partnership
Therapy Watch launches new tracker covering pulmonary arterial hypertension (PAH)
Therapy Watch Pulmonary Arterial Hypertension (PAH) is launching in the US market, with expansion into other geographies including Europe in 2024.
Research Partnership
Healthcare in the age of AI: How will artificial intelligence impact future decision-making?
Authored by: Constanza Salas, Jhon Galindo and Rachel Howard
Research Partnership
Therapy Watch launches new tracker covering Postpartum Depression
The new Therapy Watch Postpartum depression (PPD) study is the first tracker in the series to cover Psychiatry
Research Partnership